Pfizer (Essential Health / Injectable Opioids)(PFE)
HQ US35% share
pharmaceutical · input
Injectable Hospital Antibiotics (Vancomycin, Pip-Tazo, Cefepime)
IV antibiotic formulations used in hospital empiric therapy for serious bacterial infections: vancomycin (MRSA coverage), piperacillin/tazobactam/Zosyn (gram-negative/anaerobe coverage), cefepime (broad-spectrum cephalosporin). All three have been on ASHP national drug shortage lists simultaneously. Pfizer/Hospira is the dominant US manufacturer of all three; all also produced by Fresenius Kabi, Baxter, and a small number of Asian generic suppliers.
0
Source countries
4
Companies
0
Goods affected
0
Claims on record
Who makes it
Supplier companies
4 companies produce injectable hospital antibiotics (vancomycin, pip-tazo, cefepime).
Fresenius Kabi (injectable opioids)(FRE.DE)
HQ DE18% share
Hikma Pharmaceuticals PLC(HIK.L)
HQ JO15% share
Hikma Pharmaceuticals PLC (Amman Jordan; London Stock Exchange: HIK; NYSE: WHL; ~$3.1B revenue) is a major US generic injectable pharmaceutical manufacturer primarily through its Hikma Pharmaceuticals USA (formerly Roxane Laboratories) division acquired in 2016 for $2.65B. US injectable manufacturing: Columbus OH (Hikma Columbus — formerly Roxane; large sterile injectable campus) and Eatontown NJ (Hikma Eatontown). Hikma produces morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection as Schedule II controlled substance generics for US hospitals. Hikma is the largest pure-play injectable pharmaceutical company by volume in the US generics market. Jordan-headquartered and London-listed but the business is majority US generic injectables — an unusual corporate structure for what is effectively a critical US hospital drug supplier.
CordenPharma
HQ CH5% share
Swiss CDMO operating European and US API manufacturing sites; primary lipid partner for Moderna; manufactures SM-102 and full LNP lipid component portfolio including ionizable, PEGylated, phosphocholine, and plant sterols; claims largest complex lipid capacity globally